Trial Outcomes & Findings for Aerobic Exercise in Parkinson's Disease (NCT NCT03808675)
NCT ID: NCT03808675
Last Updated: 2026-03-12
Results Overview
Measures change in the severity of parkinsonism. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.
COMPLETED
NA
57 participants
Final Visit at 1 year - Baseline
2026-03-12
Participant Flow
Phone Screen (n= 186) \>\> Excluded (n= 96) * Not meeting criteria (n= 60) * Declined (n= 36) In-Person Screened \& consented (n= 90) Excluded (n=33) \- Not meeting criteria (n=33)
Enrolled \& Randomized (n=57)
Participant milestones
| Measure |
Control
Participants randomized to usual care with PD specific health education
|
Aerobic
Participants randomized to aerobic exercise
|
|---|---|---|
|
Overall Study
STARTED
|
28
|
29
|
|
Overall Study
COMPLETED
|
26
|
27
|
|
Overall Study
NOT COMPLETED
|
2
|
2
|
Reasons for withdrawal
| Measure |
Control
Participants randomized to usual care with PD specific health education
|
Aerobic
Participants randomized to aerobic exercise
|
|---|---|---|
|
Overall Study
Physician Decision
|
2
|
1
|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
Baseline Characteristics
Aerobic Exercise in Parkinson's Disease
Baseline characteristics by cohort
| Measure |
Control
n=28 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=29 Participants
Participants randomized to aerobic exercise
|
Total
n=57 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Age, Continuous
|
67.4 year
STANDARD_DEVIATION 8.2 • n=9 Participants
|
65.8 year
STANDARD_DEVIATION 6.9 • n=9 Participants
|
66.6 year
STANDARD_DEVIATION 7.5 • n=18 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=9 Participants
|
7 Participants
n=9 Participants
|
15 Participants
n=18 Participants
|
|
Sex: Female, Male
Male
|
20 Participants
n=9 Participants
|
22 Participants
n=9 Participants
|
42 Participants
n=18 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
White
|
28 Participants
n=9 Participants
|
29 Participants
n=9 Participants
|
57 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
28 Participants
n=9 Participants
|
29 Participants
n=9 Participants
|
57 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=18 Participants
|
|
Education
|
16.9 year
STANDARD_DEVIATION 3.4 • n=9 Participants
|
15.6 year
STANDARD_DEVIATION 2.5 • n=9 Participants
|
16.2 year
STANDARD_DEVIATION 3.1 • n=18 Participants
|
|
Hoehn-Yahr Stage
|
2 scores on a scale
n=9 Participants
|
2 scores on a scale
n=9 Participants
|
2 scores on a scale
n=18 Participants
|
|
Duration of PD
|
4.5 year
STANDARD_DEVIATION 3.6 • n=9 Participants
|
2.9 year
STANDARD_DEVIATION 3.1 • n=9 Participants
|
3.7 year
STANDARD_DEVIATION 3.4 • n=18 Participants
|
|
L-dopa Equivalent Daily Dose (LEDD)
|
573 mg/day
STANDARD_DEVIATION 478 • n=9 Participants
|
481 mg/day
STANDARD_DEVIATION 374 • n=9 Participants
|
526 mg/day
STANDARD_DEVIATION 427 • n=18 Participants
|
|
VO2max
|
22.3 mL/kg/min
STANDARD_DEVIATION 5.8 • n=9 Participants
|
22.9 mL/kg/min
STANDARD_DEVIATION 5.1 • n=9 Participants
|
22.6 mL/kg/min
STANDARD_DEVIATION 5.4 • n=18 Participants
|
|
2-Minute Walk Test
|
662 feet
STANDARD_DEVIATION 76 • n=9 Participants
|
639 feet
STANDARD_DEVIATION 73 • n=9 Participants
|
650 feet
STANDARD_DEVIATION 75 • n=18 Participants
|
|
MDS-UPDRS Part III Motor (OFF) score
|
19.5 score on scale
STANDARD_DEVIATION 9.9 • n=9 Participants
|
16.5 score on scale
STANDARD_DEVIATION 10.8 • n=9 Participants
|
18.0 score on scale
STANDARD_DEVIATION 10.4 • n=18 Participants
|
|
MDS-UPDRS Part I Non-motor EDL score
|
5.8 score on scale
STANDARD_DEVIATION 3.3 • n=9 Participants
|
7.0 score on scale
STANDARD_DEVIATION 5.8 • n=9 Participants
|
6.4 score on scale
STANDARD_DEVIATION 4.7 • n=18 Participants
|
|
MDS-UPDRS Part II Motor EDL
|
4.8 score on scale
STANDARD_DEVIATION 3.7 • n=9 Participants
|
4.9 score on scale
STANDARD_DEVIATION 3.7 • n=9 Participants
|
4.8 score on scale
STANDARD_DEVIATION 3.7 • n=18 Participants
|
|
MDS-UPDRS Part III Motor (ON) score
|
15.6 score on scale
STANDARD_DEVIATION 8.4 • n=9 Participants
|
13.4 score on scale
STANDARD_DEVIATION 7.9 • n=9 Participants
|
14.5 score on scale
STANDARD_DEVIATION 8.2 • n=18 Participants
|
|
MDS-UPDRS Total score
|
26.2 score on scale
STANDARD_DEVIATION 11.8 • n=9 Participants
|
25.4 score on scale
STANDARD_DEVIATION 12.1 • n=9 Participants
|
25.8 score on scale
STANDARD_DEVIATION 11.9 • n=18 Participants
|
|
MDS-UPDRS Part IV Total score
|
2.6 score on a scale
STANDARD_DEVIATION 2.4 • n=9 Participants
|
2.0 score on a scale
STANDARD_DEVIATION 2.1 • n=9 Participants
|
2.3 score on a scale
STANDARD_DEVIATION 2.2 • n=18 Participants
|
|
9-Hole Pegboard Dexterity Test (in the OFF state)
|
26.6 seconds
STANDARD_DEVIATION 5.1 • n=9 Participants
|
26.7 seconds
STANDARD_DEVIATION 8.7 • n=9 Participants
|
26.6 seconds
STANDARD_DEVIATION 7.1 • n=18 Participants
|
|
9-Hole Pegboard Dexterity Test (in the ON state)
|
24.7 seconds
STANDARD_DEVIATION 4.7 • n=9 Participants
|
24.3 seconds
STANDARD_DEVIATION 7.1 • n=9 Participants
|
24.5 seconds
STANDARD_DEVIATION 6.0 • n=18 Participants
|
|
Delayed Recall of Rey Auditory Verbal Learning Test (AVLT-Recall)
|
8.5 words
STANDARD_DEVIATION 3.1 • n=9 Participants
|
7.9 words
STANDARD_DEVIATION 3.7 • n=9 Participants
|
8.2 words
STANDARD_DEVIATION 3.4 • n=18 Participants
|
|
Flanker Inhibitory Control and Attention Test
|
92.1 normed score
STANDARD_DEVIATION 7.7 • n=9 Participants
|
89.9 normed score
STANDARD_DEVIATION 19.1 • n=9 Participants
|
91.0 normed score
STANDARD_DEVIATION 14.6 • n=18 Participants
|
|
Montreal Cognitive Assessment (MoCA)
|
24.8 score on continuous scale
STANDARD_DEVIATION 3.0 • n=9 Participants
|
24.4 score on continuous scale
STANDARD_DEVIATION 2.5 • n=9 Participants
|
24.6 score on continuous scale
STANDARD_DEVIATION 2.7 • n=18 Participants
|
|
Controlled Oral Word Association Test (COWA)
|
42.4 total count of correct words
STANDARD_DEVIATION 10.4 • n=9 Participants
|
35.1 total count of correct words
STANDARD_DEVIATION 10.7 • n=9 Participants
|
38.6 total count of correct words
STANDARD_DEVIATION 11.1 • n=18 Participants
|
|
Block Design Test (BLOCKS)
|
35.6 scores on a scale
STANDARD_DEVIATION 8.1 • n=9 Participants
|
36.8 scores on a scale
STANDARD_DEVIATION 7.4 • n=9 Participants
|
36.2 scores on a scale
STANDARD_DEVIATION 7.7 • n=18 Participants
|
|
Judgement of Line Orientation test (JLO)
|
24.4 score on test
STANDARD_DEVIATION 4.6 • n=9 Participants
|
25.4 score on test
STANDARD_DEVIATION 4.1 • n=9 Participants
|
24.9 score on test
STANDARD_DEVIATION 4.4 • n=18 Participants
|
|
Complex Figure Test -Copy (CFT-Copy)
|
27.2 score on test
STANDARD_DEVIATION 5.3 • n=9 Participants
|
28.1 score on test
STANDARD_DEVIATION 4.4 • n=9 Participants
|
27.7 score on test
STANDARD_DEVIATION 4.9 • n=18 Participants
|
|
Complex Figure Test-Recall (CFT-Recall)
|
13.5 score on test
STANDARD_DEVIATION 5.2 • n=9 Participants
|
14.4 score on test
STANDARD_DEVIATION 5.2 • n=9 Participants
|
13.9 score on test
STANDARD_DEVIATION 5.2 • n=18 Participants
|
|
Trail Making Test - A (TMT-A)
|
40.3 seconds
STANDARD_DEVIATION 15.3 • n=9 Participants
|
37.9 seconds
STANDARD_DEVIATION 24.2 • n=9 Participants
|
39.1 seconds
STANDARD_DEVIATION 20.2 • n=18 Participants
|
|
Trail Making Test - B (TMT-B)
|
82.6 seconds
STANDARD_DEVIATION 31.3 • n=9 Participants
|
85.9 seconds
STANDARD_DEVIATION 37.3 • n=9 Participants
|
84.3 seconds
STANDARD_DEVIATION 34.2 • n=18 Participants
|
|
Road Safety Error Count
|
24.4 Errors
STANDARD_DEVIATION 10.3 • n=9 Participants
|
26.0 Errors
STANDARD_DEVIATION 10.9 • n=9 Participants
|
25.2 Errors
STANDARD_DEVIATION 10.5 • n=18 Participants
|
|
Parkinson's Disease Questionnaire - 39 Summary Index
|
5.4 score on scale
STANDARD_DEVIATION 4.0 • n=9 Participants
|
7.5 score on scale
STANDARD_DEVIATION 6.5 • n=9 Participants
|
6.5 score on scale
STANDARD_DEVIATION 5.6 • n=18 Participants
|
|
Superior Longitudinal Fasciculus Radial Diffusivity (rD)
|
54.9 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=9 Participants
|
55.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=9 Participants
|
55.0 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.0 • n=18 Participants
|
|
Geriatric Depression Scale-15
|
0.79 score on test
STANDARD_DEVIATION 0.88 • n=9 Participants
|
1.03 score on test
STANDARD_DEVIATION 1.27 • n=9 Participants
|
0.91 score on test
STANDARD_DEVIATION 1.09 • n=18 Participants
|
|
Beck Anxiety Inventory (BAI)
|
1.82 score on scale
STANDARD_DEVIATION 2.70 • n=9 Participants
|
2.21 score on scale
STANDARD_DEVIATION 2.68 • n=9 Participants
|
2.02 score on scale
STANDARD_DEVIATION 2.69 • n=18 Participants
|
|
Fatigue Severity Scale (FSS)
|
1.51 score on scale
STANDARD_DEVIATION 0.66 • n=9 Participants
|
1.62 score on scale
STANDARD_DEVIATION 0.98 • n=9 Participants
|
1.57 score on scale
STANDARD_DEVIATION 0.84 • n=18 Participants
|
|
Putamen Radial Diffusivity (rD)
|
62.8 mm^2/sec * 10^-5
STANDARD_DEVIATION 2.6 • n=9 Participants
|
63.5 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.5 • n=9 Participants
|
63.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 3.1 • n=18 Participants
|
|
Cingulum Cingulate Radial Diffusivity (rD)
|
55.6 mm^2/sec * 10^-5
STANDARD_DEVIATION 5.1 • n=9 Participants
|
56.9 mm^2/sec * 10^-5
STANDARD_DEVIATION 4.0 • n=9 Participants
|
56.2 mm^2/sec * 10^-5
STANDARD_DEVIATION 4.6 • n=18 Participants
|
|
COGSTAT
|
367.6 T-score
STANDARD_DEVIATION 46.6 • n=9 Participants
|
366.3 T-score
STANDARD_DEVIATION 58.0 • n=9 Participants
|
367.0 T-score
STANDARD_DEVIATION 52.2 • n=18 Participants
|
|
Benton Visual Retention Test (BVRT)
|
6.4 score on test
STANDARD_DEVIATION 2.9 • n=9 Participants
|
6.2 score on test
STANDARD_DEVIATION 3.1 • n=9 Participants
|
6.3 score on test
STANDARD_DEVIATION 3.0 • n=18 Participants
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselineMeasures change in the severity of parkinsonism. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.
Outcome measures
| Measure |
Control
n=27 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=26 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in MDS-UPDRS Part III Motor (OFF) Score
|
0.44 score on scale
Standard Deviation 8.46
|
-2.96 score on scale
Standard Deviation 8.31
|
PRIMARY outcome
Timeframe: Final visit at 1 year - BaselineMeasures change in the executive function domains of inhibitory control and attention. Uncorrected Standard Score of the NIH Toolbox Flanker Inhibitory Control and Attention Test. The Raw Score is based on number correct × average reaction time (accuracy \& speed composite). The Uncorrected Standard Score is based on age-normed raw score with mean = 100 and SD = 15. Score range 40-160 with interpretation below: ≥ 130 - Very Superior, 115-129 - Superior, 85-114 - Average, 70-84 - Below Average, \< 70 - Impaired / markedly low attention control. Higher scores better for individual data points. Higher value better for change score.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Flanker Task
|
-1.0 scores on a scale
Standard Deviation 5.8
|
3.6 scores on a scale
Standard Deviation 18.5
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselineNumber of safety errors made during an experimental real-world road drive test, scored by a certified driving instructor per criteria in the Iowa Department of Transportation's Drive Test Scoring Standards. Higher error count score worse. Lower scores better for change score.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Road Safety Error Count
|
-2.5 Errors
Standard Deviation 9.5
|
-3.9 Errors
Standard Deviation 10.7
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselineQuestionnaire regarding activities of daily living and ability within the last month. PDQ-39 has 8 domains: Mobility (10 items) → max = 40, Activities of daily living (6 items) → max = 24, Emotional well-being (6 items) → max = 24, Stigma (4 items) → max = 16, Social support (3 items) → max = 12, Cognitions (4 items) → max = 16, Communication (3 items) → max = 12, Bodily discomfort (3 items) → max = 12. Domain Score=(Sum of item scores/Maximum possible)\*100 . The main outcome measure is PDQ-39 Summary Index (PDQ-39 SI) is the mean of the 8 domain scores (range = 0 to 100). Higher scores at datapoints are worse. Lower change score is better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in the Parkinson's Disease Questionnaire-39 (PDQ-39) Score
|
1.04 score on scale
Standard Deviation 4.18
|
-0.11 score on scale
Standard Deviation 4.64
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselinePopulation: DTI MRI was not available in all subjects.
Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.
Outcome measures
| Measure |
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Cingulum Cingulate Radial Diffusivity (rD)
|
-2.23 mm^2/sec * 10^-5
Standard Deviation 4.8
|
-1.16 mm^2/sec * 10^-5
Standard Deviation 4.10
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselinePopulation: DTI MRI was not available in all completers.
Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.
Outcome measures
| Measure |
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Superior Longitudinal Fasciculus Radial Diffusivity (rD)
|
0.12 mm^2/sec * 10^-5
Standard Deviation 0.75
|
0.09 mm^2/sec * 10^-5
Standard Deviation 1.56
|
PRIMARY outcome
Timeframe: Final Visit at 1 year - BaselinePopulation: DTI not available in all completers
Brain tissue integrity. Change in regional diffusion coefficient for radial diffusivity (rD) on DTI. Higher scores worse at individual data points. Lower scores better for change.
Outcome measures
| Measure |
Control
n=19 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=22 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Putamen Radial Diffusivity
|
-0.03 mm^2/sec * 10^-5
Standard Deviation 1.83
|
-1.01 mm^2/sec * 10^-5
Standard Deviation 1.98
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineMovement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Non-Motor Experiences of Daily Living questionnaire (Part I). Part IA It measures complex behaviors (e.g., cognition, mood) by the rater based on patient/caregiver responses. Part IB asks patient/caregiver about various body functions. Each item is rated 0-4, and the score reflect the status of each item over the past week. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score of IA and IB is reported (range 0-52). Higher scores at data points worse. Lower change scores better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in MDS-UPDRS Non-motor Experiences of Daily Living Subscale (Part I) Score
|
0.15 score on scale
Standard Deviation 4.00
|
0.41 score on scale
Standard Deviation 5.56
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineMotor function. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Motor Experiences of Daily Living questionnaire (Part II). It measures motor function based on patient/caregiver responses. Each item is rated 0-4, and the score reflect the status of each item over the past week. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-52). Higher scores worse at individual datapoints. Lower change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in MDS-UPDRS Motor Experiences of Daily Living Score (Part II)
|
1.15 score on scale
Standard Deviation 2.74
|
-0.04 score on scale
Standard Deviation 4.16
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineMeasures change in the severity of parkinsonism while antiparkinsonian medications are working. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Motor section (Part III), measured in the ON state. It measures specific signs like rigidity, tremor, bradykinesia (slowness of movement), and gait abnormalities by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-132). Higher scores worse for individual data points. Lower value better for change score.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in ON Period MDS-UPDRS Motor Examination Subscale Score (Part 3)
|
-1.88 score on scale
Standard Deviation 8.61
|
-1.41 score on scale
Standard Deviation 6.98
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineMovement Disorder Society-Unified Parkinson's Disease Rating Scale, Motor Fluctuations and Dyskinesia questionnaire. It measures duration, severity, and functional impact of dyskinesias and OFF periods by questionnaire administered by a certified rater. Each item is rated 0-4: 0 - Normal (no impairment), 1 - Slight, 2- Mild, 3 - Moderate, 4 - Severe. Total score is reported (range 0-24). Higher scores worse at data points. Lower change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in MDS-UPDRS Dyskinesia and Motor Fluctuations (Part 4)
|
0.58 score on scale
Standard Deviation 2.35
|
0.67 score on scale
Standard Deviation 2.73
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineThis is the simple addition of MDS-UPDRS Part I, II, and III (ON) total scores. This is a global measure of disease severity and encompasses motor and non-motor symptoms by subjective and objective measures. Higher scores at data points worse. Lower change scores better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Total MDS-UPDRS Score
|
-1.77 score on scale
Standard Deviation 12.13
|
-1.04 score on scale
Standard Deviation 9.77
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineMotor function. Locomotion, endurance. Distance that a participant can walk in 2-minutes at their usual speed, a measure in NIH Toolbox Motor Battery. It is measured in the ON state. Higher data point and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in 2-Minute Walk Test
|
16.0 feet
Standard Deviation 60.3
|
19.0 feet
Standard Deviation 57.8
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineAn assessment of fine motor dexterity. Participants are asked to place 9 pegs into a board with 9 holes, then remove them as quickly as possible, one hand at a time. Time to complete is reported. Part of NIH Toolbox Motor Battery. measured in the "practically defined" OFF state (after overnight, \~12 hours, withdrawal of PD medications). Higher time to complete is worse for individual data points. Lower value better for change score.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in 9-Hole Peg Board Test (OFF)
|
-0.47 seconds
Standard Deviation 3.48
|
1.24 seconds
Standard Deviation 3.50
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineAn assessment of fine motor dexterity. Participants are asked to place 9 pegs into a board with 9 holes, then remove them as quickly as possible, one hand at a time. Time to complete is reported. Part of NIH Toolbox Motor Battery. measured in the ON state (when antiparkinsonian medications are working). Higher time to complete is worse for individual data points. Lower value better for change score.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in 9-Hole Peg Board Test of NIH Toolbox Motor Battery (ON)
|
-0.51 seconds
Standard Deviation 4.23
|
0.88 seconds
Standard Deviation 7.13
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineThis is a brief cognitive screening test that measures various domains. Range 0-30. A score of 26 or over is considered to be normal. Higher score at data points and for change better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Montreal Cognitive Assessment (MOCA)
|
-0.42 score
Standard Deviation 2.97
|
0.19 score
Standard Deviation 2.75
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineComposite measure of cognitive impairment (COGSTAT) by assigning standard T scores (mean=50, SD=10) to each of the seven tests from the neuropsychological assessment battery (COWA, CFT-Copy, CFT-Recall, AVLT-Recall, BVRT, BLOCKS, and TMT \[B-A\]). Higher scores better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in COGSTAT Score
|
7.1 T-score
Standard Deviation 35.3
|
11.4 T-score
Standard Deviation 24.3
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineNumber of words created for each letter (C, F, L) of the Controlled Oral Word Association Test over 60 seconds for each letter. A test of verbal fluency, probes executive function (initiation, self-monitoring, inhibition of repeats), language (lexical access, phonemic organization), attention and working memory domains. Average healthy adult produces 12-15 words per letter. Higher score at data points and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Controlled Oral Word Association Task (COWA)
|
0.96 total words
Standard Deviation 6.07
|
3.33 total words
Standard Deviation 7.09
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineTotal score of the completion of the Block Design test. This test evaluates the ability to analyze and synthesize abstract visual patterns, manipulate spatial information mentally, and coordinate visual-motor construction skills. Raw score is sum of all points based on accuracy and speed of reproducing 14 designs. (range=0-68) - higher score and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Block Design Test (BLOCKS)
|
0.62 scores on a scale
Standard Deviation 5.15
|
0.00 scores on a scale
Standard Deviation 6.75
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineJudgement of Line Orientation test measures ability to perceive and match the angular relationships between line orientations. It is a visuospatial perception test. Raw score is sum of all correctly identified items (range 0-30). Higher score at data points and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Judgment of Line Orientation Test (JLO)
|
0.44 score on test
Standard Deviation 4.45
|
0.74 score on test
Standard Deviation 2.94
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineCognition. Memory. Number of words that can be recalled after at least 30-minutes after hearing the list. Higher scores at data points and change scores better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Delayed Recall of Rey Auditory Verbal Learning Test (AVLT-Recall)
|
0.00 score on test
Standard Deviation 2.98
|
0.08 score on test
Standard Deviation 2.77
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineAbility to copy the Rey-Osterrieth Complex Figure. Measures visuospatial construction, perceptual organization, planning, and motor control. There are 18 distinct elements, each scored 0-2, with a range of total score 0-36. Higher score at data points and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Complex Figure Test -Copy (CFT-Copy)
|
1.31 score on test
Standard Deviation 4.98
|
1.09 score on test
Standard Deviation 4.55
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineAbility to remember and draw the Rey-Osterrieth Complex Figure as accurately as possible after 30 minutes of copying it. It measures long-term visual memory and retention. There are 18 distinct elements, each scored 0-2, with a range of total score 0-36. Higher score at data points and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Complex Figure Test-Recall (CFT-Recall)
|
0.87 score on test
Standard Deviation 4.57
|
0.06 score on test
Standard Deviation 5.08
|
SECONDARY outcome
Timeframe: Final Visit at 1-year - BaselineTest of visuospatial perception and memory. 10 geometric designs are shown to the participant. Each design is viewed for 10 seconds and then reproduced from memory. We are reporting error counts (range 0-10). Higher scores worse at data points. Lower change value better.
Outcome measures
| Measure |
Control
n=27 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=26 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Benton Visual Retention Test (BVRT)
|
-0.77 score on test
Standard Deviation 2.26
|
-0.04 score on test
Standard Deviation 3.84
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineTest of processing speed, visual scanning. Time in seconds to connect numbers in ascending order. Higher time at data points worse. Lower change value better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Trail Making Test- A (TMT-A)
|
-5.3 seconds
Standard Deviation 19.0
|
-2.5 seconds
Standard Deviation 26.1
|
SECONDARY outcome
Timeframe: Final visit at 1-year - BaselineTest of set-shifting, executive function, divided attention. Time to connect letters and numbers, alternating between numbers and letters, going in ascending order. Higher time worse. Lower change value better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Trail Making Test - B (TMT-B)
|
-2.4 seconds
Standard Deviation 45.5
|
0.7 seconds
Standard Deviation 25.1
|
SECONDARY outcome
Timeframe: Final Visit at 1-year - BaselineMeasure of executive control from motor speed. Calculated as (Trail Making Test B - Trail Making Test A). Higher scores at data points worse. Lower change scores better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Trail Making Test B-A (TMT B-A)
|
2.9 seconds
Standard Deviation 37.5
|
3.2 seconds
Standard Deviation 28.4
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineSeverity of depression. Higher scores worse. Range: 0-15
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change of Geriatric Depression Scale (GDS) Score
|
0.00 score on scale
Standard Deviation 0.85
|
0.04 score on scale
Standard Deviation 1.06
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - Baselineanxiety symptoms within the last week. 21-item self-report questionnaire each describing a common anxiety symptom (physical or cognitive). Item scores: 0 - Not at all, 1 - Mildly-it did not bother me much, 2 - Moderately-it was very unpleasant but I could bear it, 3 - Severely-I could barely stand it. Range 0-63. Higher scores worse at data points. Lower change value better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Beck Anxiety Inventory (BAI) Score
|
-0.15 score on scale
Standard Deviation 1.99
|
0.93 score on scale
Standard Deviation 3.34
|
SECONDARY outcome
Timeframe: Final Visit at 1 year - BaselineSeverity of fatigue. questions on symptoms of fatigue within the last week. Format: 9 statements such as "I am easily fatigued" rated on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). Total score = sum of all items / number of items answered (i.e., average of 9 items). Range: 1 - 7. Interpretation: 1-2=No or minimal fatigue, 3-4=Moderate fatigue, ≥ 5: Severe fatigue (commonly used clinical cutoff). Higher scores worse at data points. Lower change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in Fatigue Severity Scale (FSS)
|
-0.12 score on scale
Standard Deviation 5.25
|
1.37 score on scale
Standard Deviation 8.30
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Final Visit at 1-year - BaselineMeasurement of aerobic fitness in the ON stage. VO2 max is the maximum amount of oxygen the body can use during intense exercise, serving as a key indicator of cardiovascular fitness and endurance. It is measured in milliliters of oxygen per kilogram of body weight per minute (mL/kg/min). Higher scores at data points and change score better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in VO2max on Cycle Ergometry
|
0.42 ml/kg/min
Standard Deviation 3.64
|
-0.30 ml/kg/min
Standard Deviation 3.03
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Final visit at 1-year - BaselineLEDD is a standardized measure used to compare the total dopaminergic medication load across different Parkinson's disease (PD) treatments. It converts various dopaminergic agents to a common reference - the amount equivalent to 100 mg of standard oral levodopa - allowing consistent comparison across studies and patients. Higher is worse at data points. Lower change value better.
Outcome measures
| Measure |
Control
n=26 Participants
Participants randomized to usual care with PD specific health education
|
Aerobic
n=27 Participants
Participants randomized to aerobic exercise
|
|---|---|---|
|
Change in L-dopa Equivalent Daily Dose (LEDD)
|
7.8 mg/day
Standard Deviation 233.5
|
106.5 mg/day
Standard Deviation 172.0
|
Adverse Events
Control
Aerobic
Serious adverse events
| Measure |
Control
n=28 participants at risk
Participants randomized to usual care with PD specific health education
|
Aerobic
n=29 participants at risk
Participants randomized to aerobic exercise
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Cardiac disorders
Pacemaker insertion
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Infections and infestations
COVID-19
|
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Cardiac disorders
Coronary artery bypass
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
0.00%
0/29 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Musculoskeletal and connective tissue disorders
Inguinal hernia repair
|
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Hepatobiliary disorders
Cholecystectomy
|
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
3.4%
1/29 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
Other adverse events
| Measure |
Control
n=28 participants at risk
Participants randomized to usual care with PD specific health education
|
Aerobic
n=29 participants at risk
Participants randomized to aerobic exercise
|
|---|---|---|
|
Infections and infestations
COVID-19
|
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
24.1%
7/29 • Number of events 7 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Musculoskeletal and connective tissue disorders
Pain in Extremity
|
0.00%
0/28 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
17.2%
5/29 • Number of events 5 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
|
Injury, poisoning and procedural complications
Fall
|
3.6%
1/28 • Number of events 1 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
6.9%
2/29 • Number of events 2 • from enrollment until end of follow-up, up to 1-year
PT on MedDRA v28.1 for terminology. Grading using CTCAE v6.0 as indicated. AE and SAE assessed by weekly/biweekly schedule phone calls per protocol with occasional self-reporting between calls. Events confirmed by medical record review as needed.
|
Additional Information
Ergun Uc, MD
Iowa City VA Health Care System/University of Iowa Health Care
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place